{"disease":{"id":"bile-duct-adenocarcinoma","name":"bile duct adenocarcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04596865","title":"Recurrence After Whipple's (RAW) Study","phase":"","overall_status":"COMPLETED","enrollment_count":1484,"lead_sponsor_name":"University Hospital Plymouth NHS Trust","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07161869","title":"Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma (POELH-III)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":250,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT05678218","title":"Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":245,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT04740164","title":"A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP","phase":"NA","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT04941287","title":"Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":57,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03257761","title":"Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":55,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT03602079","title":"Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Klus Pharma Inc.","has_results":false},{"nct_id":"NCT06092645","title":"Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":48,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT03951324","title":"Volumetric Laser Endomicroscopy's (VLE) Diagnostic Accuracy Validation Study: Impact on Clinical Management Study","phase":"","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Innovative Digestive Health Education and Research Inc","has_results":false},{"nct_id":"NCT04042831","title":"Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":36,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":false},{"nct_id":"NCT06383533","title":"Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":28,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT05285358","title":"Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT04164069","title":"Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Anne Noonan","has_results":false}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}